Ombitasvir/Paritaprevir/Ritonavir

BreastfeedingPediatric

FDA APPROVAL DATE: 07/22/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfuzosin, Carbamazepine, Cisapride, Copanlisib, Dihydroergotamine, Dronedarone, Efavirenz, Ergotamine, Ethinyl estradiol-containing medications, Gemfibrozil, Lovastatin, Lurasidone, Methylergonovine, Midazolam, Midostaurin, Neratinib, Phenobarbital, Phenytoin, Pimozide, Ranolazine, Rifampin, Sildenafil, Simvastatin, St John's Wort, Triazolam

PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk; contra-indicated in pregnancy when given with ribavirin

Contra-indicated in patients with moderate to severe hepatic impairment.

See also separate entries for Ombitasvir/Paritaprevir/Ritonavir (co-packaged with Dasabuvir as Viekira Pak) and Ribavirin.

Our database has 22 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.


Page last updated 06/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top